Burden of disease due to cutaneous melanoma has increased in the Netherlands since 1991

Abstract

Melanoma is becoming a great burden to Dutch society.

Clinicopathological characteristics, diagnosis and treatment of melanoma in Serbia: The Melanoma Focus Study

“…Only 17 (3.1%) patients were diagnosed with in situ melanoma, and in 217/548 (39.59%) melanoma with Breslow thickness of < 1 mm was noted. It is in line with previously published data from the single tertiary institution in Serbia, and also the main difference compared with data from Western Europe, USA and Australia, where up to 70% of patients are diagnosed as in situ or thin melanoma [4][5][6][7] . This points out to the late diagnosis, and an urgent need for efficient primary and secondary prevention measures.…”

Comparing cutaneous research funded by the US National Institutes of Health (NIH) with the US skin disease burden

“…Although over 80% of malignant melanoma is diagnosed in early stages, patients with advanced disease use 34% to 55% of total cost and experience tremendous distress. 24 There are only a handful of Food and Drug Administrationeapproved treatment options for metastatic melanoma, and many NIH studies focused on targeting biochemical pathways and novel therapeutic regimens.…”

Melanoma burden by melanoma stage: Assessment through a disease transition model

“…The disability-adjusted life years (DALY), a measure of disease burden, takes into account not only the YLL due to disease but also the years of life with disability (YLD). DALY assessments help to compare the burden of any diseases between [12,13] or within [14] countries, as well as over time [15].…”